Neurizon Therapeutics Limited has released a press release.
Progress in Recruitment for Phase II Trial in Dogs
Filed with ASX ·
6ix hasn’t read this filing yet.
Neurizon Therapeutics Limited on 6ix
Story so far
Earlier from Neurizon Therapeutics
- AGM Presentation
- Epichem new CEO and Board additions
- Appendix 3B & s708 Notice
- PharmAust Receives Pre-Approval for R&D Tax Rebates
- Epichem Export Business Receives Important WA State Awards
Later from Neurizon Therapeutics
- Presentation - Pitt Street Research Life Sciences Conference
- Expanded Site Recruitment for Phase II MPL Dog Cancer Trial
- Epichem client gives notice to end contract in February 2020
- Epichem Awarded One-Year Contract Extension from DNDi
- PharmAust Receives $700k R&D Tax Incentive Refund
Follow Neurizon Therapeutics into a list and get an email when it puts out news.
Follow Neurizon Therapeutics